229 filings
6-K
PRQR
ProQR Therapeutics N.V
9 May 24
Current report (foreign)
7:02am
6-K
PRQR
ProQR Therapeutics N.V
8 May 24
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
8:07am
6-K
PRQR
ProQR Therapeutics N.V
23 Apr 24
Current report (foreign)
7:06am
6-K
PRQR
ProQR Therapeutics N.V
19 Apr 24
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
7:06am
20-F
2023 FY
PRQR
ProQR Therapeutics N.V
Annual report (foreign)
13 Mar 24
8:43am
6-K
uudurgw5
13 Mar 24
ProQR Announces Year End 2023 Operating and Financial Results
7:10am
6-K
0fpvm3vf2drjmrzjsg8k
15 Feb 24
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
7:46am
6-K
h63rw f5c
19 Jan 24
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
7:08am
6-K
f5r2p
5 Jan 24
Current report (foreign)
7:08am
6-K
onetp8h s0d1q6
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
6-K
yp54qzx 4q7m3nytqeyo
7 Nov 23
Current report (foreign)
10:00am
6-K
w9l01hez8ju t9bepb9
27 Sep 23
ProQR Therapeutics Provides Update on Ophthalmic Assets
7:06am
6-K
2zk0c5ul
3 Aug 23
Current report (foreign)
7:15am
6-K
maud04yhozqmije
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
xovfxj
17 May 23
Current report (foreign)
4:05pm
6-K
x0g9m1gn 5olmzrj60
16 May 23
Current report (foreign)
7:15am
EFFECT
fmv63ay
25 Apr 23
Notice of effectiveness
12:15am
424B5
3h6o8h6yij1zlqabj8
24 Apr 23
Prospectus supplement for primary offering
4:30pm
CORRESP
crbv6me0h0dha2 3e
20 Apr 23
Correspondence with SEC
12:00am
6-K
99k3k6bwh21t5joe8c
18 Apr 23
Current report (foreign)
8:05am